
## Herbert Lepor

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6147194/publications.pdf Version: 2024-02-01



HEDREDTLEDOD

#	Article	IF	CITATIONS
1	The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia. New England Journal of Medicine, 2003, 349, 2387-2398.	27.0	1,780
2	Radical prostatectomy with preservation of sexual function: Anatomical and pathological considerations. Prostate, 1983, 4, 473-485.	2.3	974
3	The Efficacy of Terazosin, Finasteride, or Both in Benign Prostatic Hyperplasia. New England Journal of Medicine, 1996, 335, 533-540.	27.0	784
4	Benign Prostatic Hyperplasia Specific Health Status Measures in Clinical Research: How Much Change in the American Urological Association Symptom Index and the Benign Prostatic Hyperplasia Impact Index is Perceptible to Patients?. Journal of Urology, 1995, 154, 1770-1774.	0.4	446
5	Precise Localization of the Autonomic Nerves From the pelvic Plexus to the Corpora Cavernosa: a Detailed Anatomical Study of the Adult Male Pelvis. Journal of Urology, 1985, 133, 207-212.	0.4	430
6	TWO CONSECUTIVE SETS OF TRANSRECTAL ULTRASOUND GUIDED SEXTANT BIOPSIES OF THE PROSTATE FOR THE DETECTION OF PROSTATE CANCER. Journal of Urology, 1998, 159, 471-476.	0.4	352
7	Phase III Multicenter Placebo-Controlled Study of Tamsulosin in Benign Prostatic Hyperplasia. Urology, 1998, 51, 892-900.	1.0	349
8	A Prospective, Blinded Comparison of Magnetic Resonance (MR) Imaging–Ultrasound Fusion and Visual Estimation in the Performance of MR-targeted Prostate Biopsy: The PROFUS Trial. European Urology, 2014, 66, 343-351.	1.9	344
9	A Randomized, Placebo-Controlled Multicenter Study of the Efficacy and Safety of Terazosin in the Treatment of Benign Prostatic Hyperplasia. Journal of Urology, 1992, 148, 1467-1474.	0.4	324
10	INTRAOPERATIVE AND POSTOPERATIVE COMPLICATIONS OF RADICAL RETROPUBIC PROSTATECTOMY IN A CONSECUTIVE SERIES OF 1,000 CASES. Journal of Urology, 2001, 166, 1729-1733.	0.4	281
11	The Relative Proportion of Stromal and Epithelial Hyperplasia is Related to the Development of Symptomatic Benign Prostate Hyperplasia. Journal of Urology, 1992, 147, 1293-1297.	0.4	274
12	E-cigarette smoke damages DNA and reduces repair activity in mouse lung, heart, and bladder as well as in human lung and bladder cells. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E1560-E1569.	7.1	235
13	Idiopathic Retroperitoneal Fibrosis. Journal of Urology, 1979, 122, 1-6.	0.4	232
14	New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. European Urology, 2017, 71, 17-34.	1.9	232
15	The Efficacy of Transurethral Resection of the Prostate in Men with Moderate Symptoms of Prostatism. Journal of Urology, 1990, 143, 533-537.	0.4	196
16	The Impact of Open Radical Retropubic Prostatectomy on Continence and Lower Urinary Tract Symptoms: A Prospective Assessment Using Validated Self-Administered Outcome Instruments. Journal of Urology, 2004, 171, 1216-1219.	0.4	176
17	Nonoperative Management of Benign Prostatic Hyperplasia. Journal of Urology, 1989, 141, 1283-1289.	0.4	169
18	Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion–targeted Prostate Biopsy Outcomes. European Urology, 2016, 69, 512-517.	1.9	163

#	Article	IF	CITATIONS
19	The response to alpha blockade in benign prostatic hyperplasia is related to the percent area density of prostate smooth muscle. Prostate, 1992, 21, 297-307.	2.3	160
20	Long-Term Evaluation of Tamsulosin in Benign Prostatic Hyperplasia: Placebo-Controlled, Double-Blind Extension of Phase III Trial. Urology, 1998, 51, 901-906.	1.0	160
21	Optimization of Prostate Biopsy: the Role of Magnetic Resonance Imaging Targeted Biopsy in Detection, Localization and Risk Assessment. Journal of Urology, 2014, 192, 648-658.	0.4	156
22	Characterization of Alpha1Adrenergic Receptors in Human Benign Prostatic Hyperplasia. Journal of Urology, 1984, 132, 1226-1229.	0.4	155
23	Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Urology, 1995, 45, 406-413.	1.0	151
24	Electronic-cigarette smoke induces lung adenocarcinoma and bladder urothelial hyperplasia in mice. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 21727-21731.	7.1	151
25	Quantifying the Smooth Muscle Content of the Prostate Using Double-Immunoenzymatic Staining and Color Assisted Image Analysis. Journal of Urology, 1992, 147, 1167-1170.	0.4	139
26	THE IMPACT OF MEDICAL THERAPY ON BOTHER DUE TO SYMPTOMS, QUALITY OF LIFE AND GLOBAL OUTCOME, AND FACTORS PREDICTING RESPONSE. Journal of Urology, 1998, 160, 1358-1367.	0.4	127
27	The role of radical prostatectomy in the management of prostatic cancer. Cancer, 1987, 60, 526-537.	4.1	124
28	The Effect of Obstruction on the Developing Bladder. Journal of Urology, 1992, 148, 491-496.	0.4	119
29	Early removal of urinary catheter after radical retropubic prostatectomy is both feasible and desirable. Urology, 2001, 58, 425-429.	1.0	119
30	Doxazosin for Benign Prostatic Hyperplasia: Long-term Efficacy and Safety in Hypertensive and Normotensive Patients. Journal of Urology, 1997, 157, 525-530.	0.4	115
31	Continence Following Radical Retropubic Prostatectomy Using Self-Reporting Instruments. Journal of Urology, 2004, 171, 1212-1215.	0.4	112
32	Quantitative Morphometry of the Adult Human Bladder. Journal of Urology, 1992, 148, 414-417.	0.4	111
33	Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12â€core biopsy results. BJU International, 2016, 118, 515-520.	2.5	109
34	Followup Interval Prostate Biopsy 3 Years After Diagnosis of High Grade Prostatic Intraepithelial Neoplasia is Associated With High Likelihood of Prostate Cancer, Independent of Change in Prostate Specific Antigen Levels. Journal of Urology, 2002, 168, 1415-1418.	0.4	104
35	LOCALIZATION AND EXPRESSION OF THE alpha 1A-1 , alpha 1B AND alpha 1D-ADRENOCEPTORS IN HYPERPLASTIC AND NON-HYPERPLASTIC HUMAN PROSTATE. Journal of Urology, 1999, 161, 635-640.	0.4	96
36	Primary Bladder Closure and Bladder Neck Reconstruction in Classical Bladder Exstrophy. Journal of Urology, 1983, 130, 1142-1145.	0.4	92

#	Article	IF	CITATIONS
37	Aldehydes are the predominant forces inducing DNA damage and inhibiting DNA repair in tobacco smoke carcinogenesis. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E6152-E6161.	7.1	88
38	Contemporary evaluation of operative parameters and complications related to open radical retropubic prostatectomy. Urology, 2003, 62, 702-706.	1.0	87
39	Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy in a Consecutive Cohort of Men with No Previous Biopsy: Reduction of Over Detection through Improved Risk Stratification. Journal of Urology, 2015, 194, 1601-1606.	0.4	87
40	Alpha 1 Adrenoceptor Subtypes in the Human Prostate. Journal of Urology, 1993, 149, 640-642.	0.4	86
41	Pathologic Outcomes of Candidates for Active Surveillance Undergoing Radical Prostatectomy. Urology, 2010, 76, 689-692.	1.0	84
42	Characterization and Localization of Prostatic Alpha 1 Adrenoceptors Using Radioligand Receptor Binding on Slide-Mounted Tissue Section. Journal of Urology, 1993, 150, 2002-2006.	0.4	83
43	α-Blockers for benign prostatic hyperplasia. Current Opinion in Urology, 2012, 22, 7-15.	1.8	83
44	How Active is Active Surveillance? Intensity of Followup during Active Surveillance for Prostate Cancer in the United States. Journal of Urology, 2016, 196, 721-726.	0.4	81
45	ULTRASENSITIVE SERUM PROSTATE SPECIFIC ANTIGEN NADIR ACCURATELY PREDICTS THE RISK OF EARLY RELAPSE AFTER RADICAL PROSTATECTOMY. Journal of Urology, 2005, 173, 777-780.	0.4	77
46	ANALYSIS OF APICAL SOFT TISSUE MARGINS DURING RADICAL RETROPUBIC PROSTATECTOMY. Journal of Urology, 2001, 165, 1943-1949.	0.4	75
47	Complications, Recovery, and Early Functional Outcomes and Oncologic Control Following In-bore Focal Laser Ablation of Prostate Cancer. European Urology, 2015, 68, 924-926.	1.9	73
48	Changes in Continence and Erectile Function Between 2 and 4 Years After Radical Prostatectomy. Journal of Urology, 2009, 181, 731-735.	0.4	71
49	Prebiopsy MRI and MRI-ultrasound Fusion–targeted Prostate Biopsy in Men With Previous Negative Biopsies: Impact on Repeat Biopsy Strategies. Urology, 2015, 86, 1192-1199.	1.0	71
50	RADICAL RETROPUBIC PROSTATECTOMY REDUCES SYMPTOM SCORES AND IMPROVES QUALITY OF LIFE IN MEN WITH MODERATE AND SEVERE LOWER URINARY TRACT SYMPTOMS. Journal of Urology, 1999, 161, 1185-1188.	0.4	70
51	Ten-year Outcomes of Sexual Function After Radical Prostatectomy: Results of a Prospective Longitudinal Study. European Urology, 2014, 65, 58-65.	1.9	70
52	Site of positive surgical margins influences biochemical recurrence after radical prostatectomy. BJU International, 2009, 104, 1610-1614.	2.5	69
53	Does a nerveâ€sparing technique or potency affect continence after open radical retropubic prostatectomy?. BJU International, 2008, 102, 1581-1584.	2.5	67
54	Factors Predicting Preservation of Erectile Function in Men Undergoing Open Radical Retropubic Prostatectomy. Journal of Urology, 2009, 181, 1817-1822.	0.4	66

#	Article	IF	CITATIONS
55	Alpha 2 Adrenergic Receptors in Hyperplastic Human Prostate: Identification and Characterization Using [ 3 H] Rauwolscine. Journal of Urology, 1986, 135, 1038-1042.	0.4	64
56	Anti-desmin vs. anti-actin for quantifying the area density of prostate smooth muscle. Prostate, 1992, 20, 259-267.	2.3	64
57	The Institutional Learning Curve of Magnetic Resonance Imaging-Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years. Journal of Urology, 2018, 200, 1022-1029.	0.4	64
58	Use of Conservative Management for Low-Risk Prostate Cancer in the Veterans Affairs Integrated Health Care System From 2005-2015. JAMA - Journal of the American Medical Association, 2018, 319, 2231.	7.4	59
59	Preoperative recombinant human erythropoietin injection versus preoperative autologous blood donation in patients undergoing radical retropubic prostatectomy. Urology, 1997, 50, 727-732.	1.0	58
60	THE MECHANISM OF ADVERSE EVENTS ASSOCIATED WITH TERAZOSIN: AN ANALYSIS OF THE VETERANS AFFAIRS COOPERATIVE STUDY. Journal of Urology, 2000, 163, 1134-1137.	0.4	57
61	Nephrogenic Adenoma: Clinical Features and Therapeutic Considerations. Journal of Urology, 1981, 126, 824-826.	0.4	56
62	Long-term Continence Outcomes in Men Undergoing Radical Prostatectomy for Clinically Localized Prostate Cancer. European Urology, 2014, 65, 52-57.	1.9	56
63	DOES SITE SPECIFIC LABELING OF SEXTANT BIOPSY CORES PREDICT THE SITE OF EXTRACAPSULAR EXTENSION IN RADICAL PROSTATECTOMY SURGICAL SPECIMEN?. Journal of Urology, 1999, 162, 1352-1357.	0.4	55
64	Fifth-Generation Digital Immunoassay for Prostate-Specific Antigen by Single Molecule Array Technology. Clinical Chemistry, 2011, 57, 1712-1721.	3.2	55
65	Post-Prostatectomy Incontinence During Sexual Activity: A Single Center Prevalence Study. Journal of Urology, 2011, 186, 982-985.	0.4	54
66	The Role of Ipsilateral and Contralateral Transrectal Ultrasound-guided Systematic Prostate Biopsy in Men With Unilateral Magnetic Resonance Imaging Lesion Undergoing Magnetic Resonance Imaging-ultrasound Fusion-targeted Prostate Biopsy. Urology, 2017, 102, 178-182.	1.0	54
67	The New York University Nerve Sparing Algorithm Decreases the Rate of Positive Surgical Margins Following Radical Retropubic Prostatectomy. Journal of Urology, 2003, 169, 2147-2152.	0.4	51
68	The efficacy and safety of terazosin for the treatment of symptomatic BPH. Prostate, 1991, 18, 345-355.	2.3	50
69	Localization of the alpha 1A-Adrenoceptor in the Human Prostate. Journal of Urology, 1995, 154, 2096-2099.	0.4	50
70	Role of intraoperative biopsies during radical retropubic prostatectomy. Urology, 2004, 63, 499-502.	1.0	49
71	Focal laser ablation for localized prostate cancer: principles, clinical trials, and our initial experience. Reviews in Urology, 2014, 16, 55-66.	0.9	47
72	The Safety, Efficacy and Compliance of Terazosin Therapy for Benign Prostatic Hyperplasia. Journal of Urology, 1992, 147, 1554-1557.	0.4	46

#	Article	IF	CITATIONS
73	Endothelin-1 production and agonist activities in cultured prostate-derived cells: Implications for regulation of endothelin bioactivity and bioavailability in prostatic hyperplasia. , 1998, 34, 241-250.		46
74	Outcomes for men younger than 50 years undergoing radical prostatectomy. Urology, 2005, 66, 141-146.	1.0	46
75	Can contemporary transrectal prostate biopsy accurately select candidates for hemiâ€ablative focal therapy of prostate cancer?. BJU International, 2009, 104, 195-199.	2.5	46
76	Cigarette side-stream smoke lung and bladder carcinogenesis: inducing mutagenic acrolein-DNA adducts, inhibiting DNA repair and enhancing anchorage-independent-growth cell transformation. Oncotarget, 2015, 6, 33226-33236.	1.8	46
77	RADICAL RETROPUBLIC PROSTATECTOMY. Urologic Clinics of North America, 2001, 28, 509-519.	1.8	45
78	Risk Stratification by Urinary Prostate Cancer Gene 3 Testing Before Magnetic Resonance Imaging-Ultrasound Fusion-targeted Prostate Biopsy Among Men With No History of Biopsy. Urology, 2017, 99, 174-179.	1.0	41
79	Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359. , 1999, 39, 234-239.		40
80	Urethral Reconstruction in Boys with Classical Bladder Exstrophy. Journal of Urology, 1984, 131, 512-515.	0.4	39
81	Effect of terazosin on prostatism in men with normal and abnormal peak urinary flow rates. Urology, 1997, 49, 476-480.	1.0	39
82	THE ROLE OF PREOPERATIVE EPOETIN ALFA IN MEN UNDERGOING RADICAL RETROPUBIC PROSTATECTOMY. Journal of Urology, 2000, 163, 829-833.	0.4	39
83	Time to Return to Work and Physical Activity Following Open Radical Retropubic Prostatectomy. Journal of Urology, 2006, 176, 1420-1423.	0.4	39
84	Twitter response to the United States Preventive Services Task Force recommendations against screening with prostateâ€specific antigen. BJU International, 2015, 116, 65-71.	2.5	39
85	Muscarinic Cholinergic Receptors in Bladder Exstrophy: Insights Into Surgical Management. Journal of Urology, 1985, 134, 308-310.	0.4	38
86	THE ROLE OF BLADDER NECK BIOPSY IN MEN UNDERGOING RADICAL RETROPUBIC PROSTATECTOMY WITH PRESERVATION OF THE BLADDER NECK. Journal of Urology, 1998, 160, 2435-2439.	0.4	38
87	Inguinal Hernias in Men Undergoing Open Radical Retropubic Prostatectomy. Urology, 2007, 70, 961-964.	1.0	38
88	The effect of surgical intervention for stress urinary incontinence (UI) on postâ€prostatectomy UI during sexual activity. BJU International, 2012, 109, 1208-1212.	2.5	37
89	Alpha-blockers for the Treatment of Benign Prostatic Hyperplasia. Urologic Clinics of North America, 2016, 43, 311-323.	1.8	37
90	Prediction of Prostate Cancer Risk Among Men Undergoing Combined MRI-targeted and Systematic Biopsy Using Novel Pre-biopsy Nomograms That Incorporate MRI Findings. Urology, 2018, 112, 112-120.	1.0	36

#	Article	IF	CITATIONS
91	Does Benign Prostatic Tissue Contribute to Measurable PSA Levels After Radical Prostatectomy?. Urology, 2009, 74, 167-170.	1.0	35
92	Status of radical prostatectomy in 2009: is there medical evidence to justify the robotic approach?. Reviews in Urology, 2009, 11, 61-70.	0.9	35
93	ALTERED SMOOTH MUSCLE DEVELOPMENT AND INNERVATION IN THE LOWER GENITOURINARY AND GASTROINTESTINAL TRACT OF THE MALE HUMAN FETUS WITH MYELOMENINGOCELE. Journal of Urology, 1998, 160, 1047-1053.	0.4	33
94	Patient Centered Outcomes in Prostate Cancer Treatment: Predictors of Satisfaction Up to 2 Years After Open Radical Retropubic Prostatectomy. Journal of Urology, 2010, 184, 1977-1981.	0.4	33
95	Down Regulation of the Muscarinic Cholinergic Receptor of the Rat Prostate Following Castration. Journal of Urology, 1985, 134, 179-182.	0.4	32
96	Gleason 6 Prostate Tumors Diagnosed in the PSA Era Do Not Demonstrate the Capacity for Metastatic Spread at the Time of Radical Prostatectomy. Urology, 2013, 82, 148-153.	1.0	32
97	Generation of active TGF-? by prostatic cell cocultures using novel basal and luminal prostatic epithelial cell lines. Journal of Cellular Physiology, 2000, 184, 70-79.	4.1	31
98	Radical Prostatectomy Improves and Prevents Age Dependent Progression of Lower Urinary Tract Symptoms. Journal of Urology, 2014, 191, 412-417.	0.4	31
99	Morphometric analysis of pediatric and nonhyperplastic prostate glands: Evidence that BPH is not a unique stromal process. , 1997, 33, 177-182.		30
100	Qualitative study on decisionâ€making by prostate cancer physicians during active surveillance. BJU International, 2017, 120, 32-39.	2.5	29
101	Medical treatment of benign prostatic hyperplasia. Reviews in Urology, 2011, 13, 20-33.	0.9	28
102	The relative efficacy of terazosin versus terazosin and flutamide for the treatment of symptomatic BPH. Prostate, 1992, 20, 89-95.	2.3	27
103	Binding and Functional Properties of Alpha 1 Drenoceptors in Different Regions of the Human Prostate. Journal of Urology, 1993, 150, 253-256.	0.4	26
104	Silodosin for the Treatment of Benign Prostatic Hyperplasia: Pharmacology and Cardiovascular Tolerability. Pharmacotherapy, 2010, 30, 1303-1312.	2.6	26
105	Likert score 3 prostate lesions: Association between wholeâ€lesion ADC metrics and pathologic findings at MRI/ultrasound fusion targeted biopsy. Journal of Magnetic Resonance Imaging, 2016, 43, 325-332.	3.4	25
106	Transforming growth factor-? is an autocrine mitogen for a novel androgen-responsive murine prostatic smooth muscle cell line, PSMC1. Journal of Cellular Physiology, 2000, 185, 416-424.	4.1	24
107	The Short-Term and Long-Term Effects of Radical Prostatectomy on Lower Urinary Tract Symptoms. Journal of Urology, 2007, 178, 2397-2401.	0.4	24
108	Utility of Single-Cell Genomics in Diagnostic Evaluation of Prostate Cancer. Cancer Research, 2018, 78, 348-358.	0.9	24

#	Article	IF	CITATIONS
109	Active Surveillance Versus Watchful Waiting for Localized Prostate Cancer: A Model to Inform Decisions. European Urology, 2017, 72, 899-907.	1.9	23
110	Short-, Intermediate-, and Long-term Quality of Life Outcomes Following Radical Prostatectomy for Clinically Localized Prostate Cancer. Reviews in Urology, 2013, 15, 161-77.	0.9	23
111	Evaluation of the Effect of Endothelin-1 and Characterization of the Selective Endothelin A Receptor Antagonist PD155080 in the Prostate. Journal of Urology, 1997, 158, 253-257.	0.4	22
112	Postoperative Blood Loss Predicts the Development of Urinary Extravasation on Cystogram Following Radical Retropubic Prostatectomy. Journal of Urology, 2006, 175, 146-150.	0.4	21
113	Two-year Outcomes Following Focal Laser Ablation of Localized Prostate Cancer. European Urology Oncology, 2018, 1, 129-133.	5.4	21
114	Adoption of an Integrated Radiology Reading Room Within a Urologic Oncology Clinic: Initial Experience in Facilitating Clinician Consultations. Journal of the American College of Radiology, 2014, 11, 496-500.	1.8	20
115	Practical considerations in radical retropubic prostatectomy. Urologic Clinics of North America, 2003, 30, 363-368.	1.8	19
116	Radical Prostatectomy: Status and Opportunities for Improving Outcomes. Cancer Investigation, 2004, 22, 435-444.	1.3	19
117	Benign Prostatic Obstruction Relief in Patients with Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Enlargement Undergoing Endoscopic Surgical Procedures or Therapy with Alpha-Blockers: A Review of Urodynamic Studies. Advances in Therapy, 2017, 34, 773-783.	2.9	19
118	Multi-parametric MRI imaging of the prostate—implications for focal therapy. Translational Andrology and Urology, 2017, 6, 453-463.	1.4	19
119	Endothelins in Canine Genitourinary Tissues. Journal of Urology, 1997, 157, 1044-1048.	0.4	18
120	Blood loss during radical prostatectomy: impact on clinical, oncological and functional outcomes and complication rates. BJU International, 2012, 110, 69-75.	2.5	18
121	The Use of Magnetic Resonance Imaging to Predict Oncological Control Among Candidates for Focal Ablation of Prostate Cancer. Urology, 2018, 112, 121-125.	1.0	18
122	Open versus laparoscopic radical prostatectomy. Reviews in Urology, 2005, 7, 115-27.	0.9	18
123	Three-Year Postoperative Ultrasensitive Prostate-Specific Antigen Following Open Radical Retropubic Prostatectomy Is a Predictor for Delayed Biochemical Recurrence. European Urology, 2011, 60, 548-553.	1.9	17
124	Clinical evaluation of a novel method for the measurement of prostateâ€specific antigen, AccuPSA <sup>TM</sup> , as a predictor of 5â€year biochemical recurrenceâ€free survival after radical prostatectomy: results of a pilot study. BJU International, 2012, 109, 1770-1775.	2.5	17
125	Identifying quantitative in vivo multi-parametric MRI features for treatment related changes after laser interstitial thermal therapy of prostate cancer. Neurocomputing, 2014, 144, 13-23.	5.9	17
126	Size-adjusted Quantitative Gleason Score as a Predictor of Biochemical Recurrence after Radical Prostatectomy. European Urology, 2016, 70, 248-253.	1.9	17

8

#	Article	IF	CITATIONS
127	The Role of Minimally Invasive Surgical Techniques in the Management of Large-gland Benign Prostatic Hypertrophy. Reviews in Urology, 2015, 17, 140-9.	0.9	17
128	This Month in Investigative Urology: Alpha Adrenergic Innervation of the Prostate: Insights into Pharmacotherapy of BPH. Journal of Urology, 1990, 143, 590-591.	0.4	16
129	Mitogenic activation of human prostate-derived fibromuscular stromal cells by bradykinin. British Journal of Pharmacology, 1999, 127, 220-226.	5.4	16
130	Exploring Variation in the Use of Conservative Management for Low-risk Prostate Cancer in the Veterans Affairs Healthcare System. European Urology, 2020, 77, 683-686.	1.9	16
131	Concordance and Performance of 4Kscore and SelectMDx for Informing Decision to Perform Prostate Biopsy and Detection of Prostate Cancer. Urology, 2020, 141, 119-124.	1.0	16
132	Detection of prostate cancer in males with prostatism. Prostate, 1994, 25, 132-140.	2.3	15
133	Prostate-Specific Antigen Doubling Time Is a Reliable Predictor of Imageable Metastases in Men with Biochemical Recurrence After Radical Retropubic Prostatectomy. Urology, 2008, 71, 501-505.	1.0	15
134	Neurovascular bundle resection: Does it improve the margins?. Urologic Oncology: Seminars and Original Investigations, 2010, 28, 215-218.	1.6	15
135	Informational needs during active surveillance for prostate cancer: A qualitative study. Patient Education and Counseling, 2018, 101, 241-247.	2.2	15
136	Multiparametric magnetic resonance imaging identifies significant apical prostate cancers. BJU International, 2018, 121, 239-243.	2.5	13
137	Early oncological control following partial gland cryo-ablation: a prospective experience specifying reflex MRI guided biopsy of the ablation zone. Prostate Cancer and Prostatic Diseases, 2021, 24, 114-119.	3.9	13
138	Application of the PRECISION Trial Biopsy Strategy to a Contemporary Magnetic Resonance Imaging-Targeted Biopsy Cohort—How Many Clinically Significant Prostate Cancers are Missed?. Journal of Urology, 2021, 205, 740-747.	0.4	13
139	10-Year Mortality After Radical Prostatectomy for Localized Prostate Cancer in the Prostate-specific Antigen Screening Era. Urology, 2015, 86, 783-789.	1.0	12
140	5-Year Outcomes Following Focal Laser Ablation of Prostate Cancer. Urology, 2021, 155, 124-129.	1.0	12
141	Comparison of healthâ€related qualityâ€ofâ€life outcomes for Africanâ€American and Caucasianâ€American men after radical prostatectomy. BJU International, 2012, 110, 1129-1133.	2.5	11
142	Uroplakins play conserved roles in egg fertilization and acquired additional urothelial functions during mammalian divergence. Molecular Biology of the Cell, 2018, 29, 3128-3143.	2.1	11
143	Predicting continence following radical prostatectomy. Current Urology Reports, 2001, 2, 248-252.	2.2	9
144	Testosterone Deficiency and the Prostate. Urologic Clinics of North America, 2016, 43, 203-208.	1.8	9

#	Article	IF	CITATIONS
145	Effect of Long-Term Hormonal Therapy (vs Short-Term Hormonal Therapy): A Secondary Analysis of Intermediate-Risk Prostate Cancer Patients Treated on NRG Oncology RTOG 9202. International Journal of Radiation Oncology Biology Physics, 2017, 97, 511-515.	0.8	9
146	Copolymerization of single-cell nucleic acids into balls of acrylamide gel. Genome Research, 2020, 30, 49-61.	5.5	9
147	Transabdominal Sonocystography: A Novel Technique to Assess Vesicourethral Extravasation Following Radical Prostatectomy. Journal of Urology, 2008, 180, 2459-2462.	0.4	8
148	Natural History of Pathologically Benign Cancer Suspicious Regions on Multiparametric Magnetic Resonance Imaging Following Targeted Biopsy. Journal of Urology, 2015, 194, 1234-1240.	0.4	8
149	A prospective comparative analysis of the accuracy of HistoScanning and multiparametric magnetic resonance imaging in the localization of prostate cancer among men undergoing radical prostatectomy. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 3.e1-3.e8.	1.6	8
150	Oncological control following partial gland ablation for intermediate-risk prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 671-677.	1.6	8
151	Interaction between race and prostate cancer treatment benefit in the Veterans Health Administration. Cancer, 2021, 127, 3985-3990.	4.1	8
152	Binding and functional properties of doxazosin in the human prostate adenoma and canine brain. Prostate, 1990, 16, 29-38.	2.3	7
153	α1-Adrenoceptor properties of terazosin HCl and its enantiomers in the human prostate and canine brain. Prostate, 1992, 20, 159-165.	2.3	7
154	Editorial: Benign Prostatic Hyperplasia. Journal of Urology, 1995, 153, 1540-1542.	0.4	7
155	The Preoperative Use of Erythropoietin Stimulating Proteins Prior to Radical Prostatectomy Is Not Associated With Increased Cardiovascular or Thromboembolic Morbidity or Mortality. Urology, 2010, 75, 1424-1428.	1.0	7
156	Detection of prostate cancer local recurrence following radical prostatectomy: assessment using a continuously acquired radial golden-angle compressed sensing acquisition. Abdominal Radiology, 2017, 42, 290-297.	2.1	7
157	Focal Ablation of Prostate Cancer. Reviews in Urology, 2018, 20, 145-157.	0.9	7
158	Quantitative evaluation of treatment related changes on multi-parametric MRI after laser interstitial thermal therapy of prostate cancer. Proceedings of SPIE, 2013, 8671, 86711F.	0.8	6
159	Long-Term Continence Outcomes in Men Undergoing Radical Prostatectomy: A Prospective 15-Year Longitudinal Study. Journal of Urology, 2018, 200, 626-632.	0.4	6
160	Does Open Radical Retropubic Prostatectomy Decrease the Risk of Acute Urinary Retention?. Urology, 2008, 72, 821-824.	1.0	4
161	Risk of Small Bowel Obstruction After Robot-Assisted <i>vs</i> Open Radical Prostatectomy. Journal of Endourology, 2016, 30, 1291-1295.	2.1	4
162	Characterization of 1,4, Dihydropyridine Calcium Channel Binding Sites in the Human Prostate. Journal of Urology, 1990, 144, 1539-1542.	0.4	3

#	Article	IF	CITATIONS
163	The shortâ€ŧerm use of erythropoetinâ€stimulating agents: impact on the biochemical recurrence of prostate cancer. BJU International, 2011, 108, 1582-1587.	2.5	3
164	Long-term Satisfaction After Open Radical Prostatectomy. Urology, 2015, 85, 1130-1136.	1.0	3
165	Surgical Treatment of Prostate Carcinoma. Journal of Urology, 2017, 197, S41-S42.	0.4	3
166	Aetiology and management of earlier vs later biochemical recurrence after retropubic radical prostatectomy. BJU International, 2017, 120, 505-510.	2.5	3
167	Optimizing patient selection for focal therapy—mapping and ablating the index lesion. Translational Andrology and Urology, 2018, 7, S519-S525.	1.4	3
168	Health state utilities among contemporary prostate cancer patients on active surveillance. Translational Andrology and Urology, 2018, 7, 197-202.	1.4	3
169	Effect of finasteride and/or terazosin on serum PSA: Results of VA cooperative study #359. Prostate, 1999, 39, 234-239.	2.3	3
170	Magnetic resonance imaging in prostate cancer. Translational Andrology and Urology, 2017, 6, 343-344.	1.4	3
171	Juxta-adrenal Ancient Schwannoma: A Rare Retroperitoneal Tumor. Reviews in Urology, 2015, 17, 97-101.	0.9	3
172	Prostate Cancer Screening and Management in Solid Organ Transplant Candidates and Recipients. Reviews in Urology, 2019, 21, 85-92.	0.9	3
173	Combination Therapy for Non-neurogenic Male Lower Urinary Tract Symptoms: 1 + 1 Does Not Equal 2. European Urology, 2013, 64, 244-246.	1.9	2
174	Is Targeted Therapy of Prostate Cancer Ready for Prime Time?. European Urology, 2016, 69, 221-222.	1.9	2
175	Morphometric analysis of pediatric and nonhyperplastic prostate glands: Evidence that BPH is not a unique stromal process. Prostate, 1997, 33, 177-182.	2.3	2
176	Using the 4Kscore Test and Magnetic Resonance Imaging Results to Avoid Unnecessary Prostate Biopsy. Reviews in Urology, 2015, 17, 1-2.	0.9	2
177	A Prospective Pilot Study Investigating Performance of 18F-Fluciclovine PET Imaging for Detection of Prostate Cancer 2 Years Following Primary Partial Gland Cryoablation. Nuclear Medicine and Molecular Imaging, 0, , .	1.0	2
178	80 RADICAL PROSTATECTOMY (RP) PREVENTS AGE-DEPENDENT PROGRESSION OF LOWER URINARY TRACT SYMPTOMS (LUTS). Journal of Urology, 2013, 189, .	0.4	1
179	Transforming growth factorâ€Ĥ² is an autocrine mitogen for a novel androgenâ€responsive murine prostatic smooth muscle cell line, PSMC1. Journal of Cellular Physiology, 2000, 185, 416-424.	4.1	1
180	Novel role of X-linked inhibitor of apoptosis protein (XIAP) in bladder cancer cell invasion and prediction of disease progression Journal of Clinical Oncology, 2014, 32, e15504-e15504.	1.6	1

#	Article	IF	CITATIONS
181	Editorial Comment. Urology, 2010, 76, 933.	1.0	О
182	Radical Prostatectomy for Long-Term Functional and Oncologic Outcomes. European Urology, 2012, 61, 676-678.	1.9	0
183	Editorial Comment. Urology, 2013, 82, 1353-1354.	1.0	о
184	Editorial Comment. Urology, 2014, 84, 1458.	1.0	0
185	Reply. Urology, 2015, 86, 788-789.	1.0	0
186	Editorial Comment. Urology, 2016, 91, 116-117.	1.0	0
187	Editorial Comment. Urology, 2016, 93, 74.	1.0	0
188	The Challenge for Urologists Is to Screen, Detect, and Treat Prostate Cancer "Smarter― Will Ablative Technology Result in Smarter Treatment?. European Urology, 2016, 70, 456-457.	1.9	0
189	Editorial Comment. Journal of Urology, 2017, 198, 343-344.	0.4	Ο
190	Long-term Natural History of Lower Urinary Tract Symptoms Following Radical Retropubic Prostatectomy: A Prospective 15-Year Longitudinal Study. Urology, 2018, 120, 167-172.	1.0	0
191	EDITORIAL COMMENT. Urology, 2019, 133, 179.	1.0	0
192	MRI predicts prostatic urethral involvement in men undergoing radical prostatectomy: implications for cryo-ablation of localized prostate cancer. World Journal of Urology, 2021, 39, 3309-3314.	2.2	0
193	AUTHOR REPLY. Urology, 2021, 155, 129.	1.0	Ο
194	IL-9 Incidence prevention and management of urinary incontinence following radical prostatectomy (RP). Japanese Journal of Urology, 2004, 95, 273-274.	0.1	0
195	S7 Prostatic Stem Cells : Location and Biological Properties. Japanese Journal of Urology, 2006, 97, 147.	0.1	0
196	Focal Ablation of Prostate Cancer. Reviews in Urology, 2018, 20, 107-111.	0.9	0